MC10, a Massachusetts-based startup specializing in wearable digital health sensors, and AbbVie, a global biopharmaceutical company, are working together on clinical trials in patients with multiple sclerosis (MS) using the BioStamp nPoint system.
The new partnership aims to explore the use of data from the nPoint® System in order to provide unique insights into MS clinical studies.
“We are excited to work with a world leader in CNS therapies and look forward to exploring novel data and metrics that help to advance clinical development,” said Dr Arthur Combs, Chief Medical Officer of MC10.
BioStamp nPoint System, which received 510(k) from the FDA, was developed for use in clinical trials and other applications for the continuous collection of physiological data. The system is optimized for both in-home and in-clinic use. The BioStamp nPoint System reports vital signs, activity and postural classifications and a suite of sleep metrics. Today, numerous pharmaceutical companies and academic research across several therapeutic areas use this system, said MC10 in a press release.
Dr. Michael Gold, Vice President, Development Neurosciences, of AbbVie said:
“We are excited to explore the BioStamp nPoint System’s ability to unobtrusively collect clinically relevant data continuously from subjects in more natural settings. This technology has the potential to improve the quality of data we collect and at the same time reduce the burden on study participants.”
Based in Lexington, Massachusetts, MC10 combines its proprietary ultra-thin, flexible body-worn sensors with advanced analytics to unlock health insights from physiological data.
Lake Bluff, Illinois-based AbbVie was founded in 2013 as a spin-off of Abbott Laboratories.